In this presentation, Dr. Adam Cheifetz will discuss the best practices of therapeutic drug monitoring (TDM) in the treatment and management of inflammatory bowel disease (IBD) following his recent publication in the August 2021 issue of The American Journal of Gastroenterology entitled “A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.”
In addition to reviewing the clinical utility of both reactive and proactive TDM, Dr. Cheifetz will conclude with a discussion on precision-guided dosing which is positioned to fundamentally change the future of biologic therapy optimization in IBD.
Participants will have the opportunity to interact with Dr. Cheifetz and are encouraged to ask questions and share their experiences in the management of IBD.
Adam S. Cheifetz, M.D.
Director, Center for Inflammatory Bowel Disease
Assistant Director, Advanced Fellowship in
Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Professor of Medicine
Director, Gastroenterology Clerkship Elective
Harvard Medical School